Featured
FDA Approves Pembrolizumab as Adjuvant therapy for Early-stage Resectable Non-small Cell Lung Cancer
On January 26, 2023, the U.S. Food and Drug Administration
More
By Paolo Tarantino, MD Dana-Farber Cancer Institute/Harvard Medical School
More
More news
> All Top Headlines
Expert Opinion
See all »
By Paolo Tarantino, MD Dana-Farber Cancer Institute/Harvard Medical School “Overall, a major shift in the way we treat breast cancer has
More
Local Oncologist Involved with the Binaytara Foundation Since 2019 Meet Dr. Fengting Yan, one of our wonderful Education Committee members! Dr. Yan
More
In this blog article, Dr. Dan Milner, Chief Medical Officer of the American Society for Clinical Pathology, discusses his experience about his
Morecancer health disparities
See all »
Senior Fellows and Early Career Oncologists Interested in Cancer Health Disparities are Encouraged to Apply Interested in being mentored by oncologists and
More
Submit Your Research for Presentation at Our Cancer Disparities Summit The Binaytara Foundation invites you to submit your research for our Summit
More
Local Oncologist Involved with the Binaytara Foundation Since 2019 Meet Dr. Fengting Yan, one of our wonderful Education Committee members! Dr. Yan
More
The addition of Dr. Anand Nayak and Mr. Santosh Ray’s Expertise Has Led to an Enhanced Histopathology Laboratory Dr. Anand Kumar Nayak
MoreNew Approvals
See all »
FDA Approves Pembrolizumab as Adjuvant therapy for Early-stage Resectable Non-small Cell Lung Cancer
On January 26, 2023, the U.S. Food and Drug Administration approved Pembrolizumab for patients with resectable, stage IB (≥4cm)-IIIA (as per the
More
On January 19, 2023, the U.S. Food and Drug Administration granted accelerated approval to Tucatinib plus Trastuzumab for adult patients with RAS
More